Unknown

Dataset Information

0

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.


ABSTRACT: Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited. This open-label study assessed the efficacy and safety of deferiprone in patients with SCD or other anemias receiving chronic transfusion therapy. A total of 228 patients (mean age: 16.9 [range, 3-59] years; 46.9% female) were randomized to receive either oral deferiprone (n = 152) or subcutaneous deferoxamine (n = 76). The primary endpoint was change from baseline at 12 months in liver iron concentration (LIC), assessed by R2* magnetic resonance imaging (MRI). The least squares mean (standard error) change in LIC was -4.04 (0.48) mg/g dry weight for deferiprone vs -4.45 (0.57) mg/g dry weight for deferoxamine, with noninferiority of deferiprone to deferoxamine demonstrated by analysis of covariance (least squares mean difference 0.40 [0.56]; 96.01% confidence interval, -0.76 to 1.57). Noninferiority of deferiprone was also shown for both cardiac T2* MRI and serum ferritin. Rates of overall adverse events (AEs), treatment-related AEs, serious AEs, and AEs leading to withdrawal did not differ significantly between the groups. AEs related to deferiprone treatment included abdominal pain (17.1% of patients), vomiting (14.5%), pyrexia (9.2%), increased alanine transferase (9.2%) and aspartate transferase levels (9.2%), neutropenia (2.6%), and agranulocytosis (0.7%). The efficacy and safety profiles of deferiprone were acceptable and consistent with those seen in patients with transfusion-dependent thalassemia. This trial study was registered at www://clinicaltrials.gov as #NCT02041299.

SUBMITTER: Kwiatkowski JL 

PROVIDER: S-EPMC8864642 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.

Kwiatkowski Janet L JL   Hamdy Mona M   El-Beshlawy Amal A   Ebeid Fatma S E FSE   Badr Mohammed M   Alshehri Abdulrahman A   Kanter Julie J   Inusa Baba B   Adly Amira A M AAM   Williams Suzan S   Kilinc Yurdanur Y   Lee David D   Tricta Fernando F   Elalfy Mohsen S MS  

Blood advances 20220201 4


Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited. This open-label study assessed the efficacy and safety of deferiprone in patients with SCD or other anemias receiving chronic transfusion therapy. A total of 228 patients (mean age: 16.9 [range, 3-59] ye  ...[more]

Similar Datasets

| S-EPMC9979751 | biostudies-literature
| S-EPMC4490296 | biostudies-literature
| S-EPMC3078566 | biostudies-literature
| S-EPMC6760189 | biostudies-literature
| S-EPMC6489379 | biostudies-literature
| S-EPMC10860110 | biostudies-literature
| S-EPMC6626578 | biostudies-literature
| S-EPMC3321852 | biostudies-literature